DBV Technologies (DBVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DBV Technologies (DBVT) has a cash flow conversion efficiency ratio of -0.209x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.19 Million) by net assets ($168.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DBVT defensive interval ratio to measure how many days the company can operate on defensive assets alone.
DBV Technologies - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DBV Technologies's cash flow conversion efficiency has evolved over time, based on yearly financial data.
DBV Technologies Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DBV Technologies ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frequentis AG
VI:FQT
|
-0.003x |
|
Ji'an Mankun Technology Co. Ltd. A
SHE:301132
|
0.015x |
|
Jayaswal Neco Industries Limited
NSE:JAYNECOIND
|
0.236x |
|
GlaxoSmithKline PLC
LSE:GSK
|
0.141x |
|
NCR Voyix Corporation
NYSE:VYX
|
0.037x |
|
Daewoong Pharma
KO:069620
|
0.057x |
|
Mcmillan Shakespeare Ltd
AU:MMS
|
-0.294x |
|
NanJi ECommerce Co Ltd
SHE:002127
|
0.029x |
Annual Cash Flow Conversion Efficiency for DBV Technologies (2011–2025)
The table below shows the annual cash flow conversion efficiency of DBV Technologies from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see DBVT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $168.77 Million | $-121.18 Million | -0.718x | +81.18% |
| 2024-12-31 | $27.39 Million | $-104.47 Million | -3.815x | -571.38% |
| 2023-12-31 | $140.19 Million | $-79.65 Million | -0.568x | -98.36% |
| 2022-12-31 | $194.45 Million | $-55.70 Million | -0.286x | +73.79% |
| 2021-12-31 | $99.03 Million | $-108.24 Million | -1.093x | -35.63% |
| 2020-12-31 | $205.49 Million | $-165.61 Million | -0.806x | -4.95% |
| 2019-12-31 | $193.19 Million | $-148.35 Million | -0.768x | +31.83% |
| 2018-12-31 | $165.78 Million | $-186.74 Million | -1.126x | -28.02% |
| 2017-12-31 | $182.88 Million | $-160.91 Million | -0.880x | -258.89% |
| 2016-12-31 | $267.90 Million | $-65.68 Million | -0.245x | -195.04% |
| 2015-12-31 | $384.24 Million | $-31.93 Million | -0.083x | +53.34% |
| 2014-12-31 | $182.22 Million | $-32.45 Million | -0.178x | +45.72% |
| 2013-12-31 | $74.09 Million | $-24.31 Million | -0.328x | -23.20% |
| 2012-12-31 | $66.84 Million | $-17.80 Million | -0.266x | +49.14% |
| 2011-12-31 | $19.79 Million | $-10.36 Million | -0.524x | -- |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of i… Read more